Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-valvular Atrial Fibrillation Clear all
Completed No phase listed Observational

Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients

NCT02461602
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Pasadena, California • Coral Springs, Florida • Port Charlotte, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Not applicable Interventional

Use of Electronic Personal Health Records to Improve Medication Adherence

NCT03018197
View directory record Official record
Conditions
Atrial Fibrillation, Medication Adherence
Interventions
Medication Education
Other
Lead sponsor
Parkview Health
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Not applicable Interventional

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

NCT02928497
View directory record Official record
Conditions
Stroke
Interventions
WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control)
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
71
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 9:09 PM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

NCT02690155
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
38,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

NCT00262600
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
warfarin, Dabigatran dose 1, Dabigatran dose 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
18,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
374
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 21, 2026, 9:09 PM EDT
Completed No phase listed Observational Results available

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

NCT02043808
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
25,586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Jul 21, 2026, 9:09 PM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

NCT02687854
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
18,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Phase 4 Interventional Results available

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

NCT01493557
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
pantoprazole, Pradaxa (dabigatran etexilate), Pradaxa, within 30 minutes after a meal
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Not applicable Interventional Results available

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

NCT03795298
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
WATCHMAN FLX Implant, Market-approved OAC
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Phase 4 Interventional Results available

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

NCT01896297
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Pradaxa, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Hot Springs, Arkansas • Fremont, California • Moreno Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Jul 21, 2026, 9:09 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF

NCT04956978
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Patient Decision Support Tool
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 21, 2026, 9:09 PM EDT
Completed No phase listed Observational Results available

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

NCT03026556
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
42,534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Not applicable Interventional Results available

Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology

NCT02702271
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
WATCHMAN FLX
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jul 21, 2026, 9:09 PM EDT
Completed No phase listed Observational Results available

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

NCT04681482
View directory record Official record
Conditions
Atrial Fibrillation, Obesity, Anticoagulants
Interventions
Apixaban
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
107,383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

NCT00504556
View directory record Official record
Conditions
Atrial Fibrillation, Thromboembolism
Interventions
Edoxaban (DU-176b), warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
22
States / cities
Huntsville, Alabama • Anaheim, California • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 21, 2026, 9:09 PM EDT
Suspended Not applicable Interventional

A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

NCT06168942
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
Interventions
Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 9:09 PM EDT
Not listed Phase 4 Interventional

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

NCT03088072
View directory record Official record
Conditions
Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure
Interventions
Edoxaban, WATCHMAN LAA Closure, Aspirin and Clopidogrel, Aspirin and Warfarin
Drug · Device
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 21, 2026, 9:09 PM EDT
Active, not recruiting Not applicable Interventional

An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation

NCT05565599
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
Left Atrial Appendage Closure
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Tucson, Arizona • Jonesboro, Arkansas • La Jolla, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Stroke Feasibility Study

NCT01997905
View directory record Official record
Conditions
Atrial Fibrillation, AFib
Interventions
AtriClip LAA Exclusion Device
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
St. Helena, California • Miami, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Jul 21, 2026, 9:09 PM EDT
Withdrawn No phase listed Observational

Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)

NCT03508258
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Phase 4 Interventional Results available

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

NCT02608099
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Interrupted apixaban, Uninterrupted apixaban
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Huntsville, Alabama • Mission Viejo, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Jul 21, 2026, 9:09 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

NCT00742859
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
betrixaban, Warfarin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Anaheim, California • Colorado Springs, Colorado • Melbourne, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jul 21, 2026, 9:09 PM EDT
Terminated Phase 3 Interventional Results available

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

NCT03839355
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Jul 21, 2026, 9:09 PM EDT
Completed No phase listed Observational

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

NCT03359876
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Jul 21, 2026, 9:09 PM EDT